Fosun Pharma unit, BioNTech to form joint venture to make up to 1 billion doses of Covid-19 vaccine in China
- The Fosun unit will contribute up to US$100 million of assets including cash and a manufacturing facility, while BioNTech will chip in the licence and know-how
- Fosun is BioNTech’s exclusive partner for the vaccine in mainland China, Hong Kong, Taiwan and Macau
Shanghai Fosun Pharmaceutical Industry Development will contribute up to US$100 million of assets including cash and a manufacturing facility, while BioNTech will chip in the licence and know-how to produce the vaccine of the same value. Each party will own half of the venture.
Fosun will also provide loans to the planned 15-year joint venture – to be incorporated in Shanghai – of up to €150 million (US$182.4 million), besides arranging other credit facilities.
Germany has opposed the US-backed proposal first initiated by India and South Africa last fall, saying protection of intellectual property is key to encouraging innovation and should not be taken away.
Supporters, including some European Union states like France and Italy, have said it will let more companies manufacture the vaccine that is needed to save lives and bring back the global economy to normal, especially in developing nations.
mRNA vaccines work by introducing a molecule coded for a disease-specific protein, which can “coach” the body’s immune system to produce antibodies and generate immune responses against the virus.
Its marketing success was made possible by a partnership with US pharmaceutical giant Pfizer, which has an extensive network for clinical trials, besides strong manufacturing and sales capabilities.
Pfizer expected revenue from the vaccine to account for over a third of its sales this year, based on contracts to deliver 1.6 billion vaccine doses this year.
International community races to help India tackle worsening Covid-19 outbreak
Fosun is BioNTech’s exclusive partner for the vaccine in mainland China, Hong Kong, Taiwan and Macau.
Some 318 million of Covid-19 vaccines have been administered in China so far, according to Our World in Data, primarily products developed by state-owned Sinopharm and privately controlled Sinovac Biotech.
The proposed joint venture’s board will have six directors, Fosun said. Fosun will nominate candidates for the positions of general manager and vice-president of finance, while BioNTech will nominate the deputy general manager and vice-president of compliance.